Search Results for keywords:"controlled substances"

Veranova, L.P. has applied to the Drug Enforcement Administration (DEA) to become an importer of specific controlled substances. These substances include Coca Leaves, raw Opium, Poppy Straw Concentrate, Thebaine, Noroxymorphone, and Fentanyl. The company intends to use these materials to manufacture active pharmaceutical ingredients and reference standards for testing purposes. The DEA invites public comments or objections by March 17, 2025, and requests for a hearing must be sent to the designated DEA addresses.

Patheon API Services Inc. has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of certain controlled substances. This registration is intended to support the clinical trials of their customers. Interested parties are invited to submit comments or objections electronically through the Federal eRulemaking Portal by June 17, 2025. They may also request a hearing on the application by the same date.

Organic Standards Solutions International, LLC has applied to the Drug Enforcement Administration (DEA) to register as an importer of certain controlled substances. The company aims to import substances like Marihuana Extract, Marihuana, and a synthetic version of Tetrahydrocannabinols to create analytical reference standards for customers. The public can comment or request a hearing on this application by January 6, 2025, through the Federal eRulemaking Portal. Permits will be approved only if the business activities align with legal requirements, and the company is not authorized to import FDA-approved or non-approved finished products for sale.

The Department of Justice's Drug Enforcement Administration (DEA) is seeking public comments on its information collection proposal related to electronic prescriptions for controlled substances. This collection is critical for verifying practitioners' identities and managing their access to prescription systems securely. Affected groups include businesses, non-profits, and government entities, required to respond mandatorily. The DEA estimates that the total annual time burden for respondents will be 107,733 hours, with no additional cost burdens. Comments on the proposal will be accepted until March 3, 2025.

The Drug Enforcement Administration (DEA) has announced that GGGYI LLC has applied to be registered as a bulk manufacturer of certain controlled substances, specifically marihuana, for research purposes. This application is part of DEA's program to oversee the cultivation and distribution of marihuana for scientific and medical research under strict regulations. Interested parties, such as existing manufacturers or applicants, can submit comments or objections regarding this application by April 26, 2021. The DEA will evaluate the application based on applicable laws and regulations to ensure proper safeguards against misuse are in place.

The Drug Enforcement Administration (DEA) has revoked Rachel Jackson's DEA Certificate of Registration because she is not licensed to handle controlled substances in Maine. Jackson voluntarily surrendered her Maine physician assistant license, making her ineligible to practice or register with the DEA. Despite being alerted about the situation and the chance to request a hearing, Jackson did not respond, leading to a default determination and subsequent action to revoke her registration. The order for revocation is effective from April 21, 2025.

The Drug Enforcement Administration (DEA) revoked the registration of Hazem Barmada, M.D., allowing him to handle controlled substances in Mississippi because he no longer has a valid medical license in the state. The Mississippi State Board of Medical Licensure had accepted his voluntary surrender of the license in 2021, making him ineligible to practice medicine and handle controlled substances there. As holding a valid state license is necessary for DEA registration, Dr. Barmada’s registration was revoked, and any pending applications related to it were denied. This decision will take effect on April 21, 2025.

The Drug Enforcement Administration (DEA) has revoked the DEA registration of Xubex Community Pharmacy in Casselberry, Florida. This decision was made because the pharmacy dispensed controlled substances, specifically Schedule II drugs like oxycodone and hydromorphone, without prescriptions. The DEA considered these actions a threat to public health and safety, demonstrating that the pharmacy cannot be trusted to comply with legal requirements. Furthermore, the pharmacy did not request a hearing to dispute these conclusions, leading to the default revocation of its registration.

The Drug Enforcement Administration (DEA) has decided to revoke William Needham's Certificate of Registration to handle controlled substances in Mississippi. This decision was made because Needham is no longer authorized to practice nursing in Mississippi after his nursing licenses were revoked. The DEA issued an Order to Show Cause, but Needham did not respond, which led to a default judgment against him. Consequently, without a state license, he cannot legally dispense controlled substances and will not have his DEA registration or any related applications renewed.

The Drug Enforcement Administration (DEA) has revoked the Certificate of Registration of James T. Craig, D.D.S., a dentist from Colorado, meaning he can no longer handle controlled substances. This decision was made because his dental license in Colorado was revoked, and he lacked the necessary state authority to dispense controlled substances. The DEA notified Craig of his right to a hearing, which he opted not to request, resulting in an automatic admission of the allegations against him. Consequently, any pending applications from Craig to renew or modify his registration have also been denied.